{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T02:19:36Z","timestamp":1789006776552,"version":"build-2803163510"},"reference-count":34,"publisher":"Mattioli1885","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:p>Introduction: Treatment of hidradenitis suppurativa (HS) remains a challenge in clinical practice for dermatologists. Although the efficacy and safety of secukinumab (SEC) in the treatment of HS has been demonstrated in phase III studies, real-world data is limited. Objectives: We conducted a retrospective multicenter study to evaluate the efficacy and safety of SEC treatment in HS patients in real-world settings. Methods: Adult patients who were diagnosed with HS and used SEC for at least 3 months were included in the study. Results: A total of 31 patients were included in the study; 14 of them (45.2%) were female. The mean age was 39.32 \u00b1 10.26 years, and the mean disease duration was 11.77 \u00b1 7.99 years. Nine (29%) patients were biologic-naive and 10 (32.3%) were adalimumab-naive. Disease severity was Hurley I in 7 patients (22.6%), Hurley II in 9 patients (29%), and Hurley III in 15 patients (48.4%). The Hidradenitis Suppurativa Clinical Response (HiSCR) was achieved in 20 patients (64.5%) in the third month of treatment. SEC treatment was discontinued due to primary ineffectiveness in 9 (29%) patients, secondary ineffectiveness in 1 (3.2%) patient, adverse effects in 1 (3.2%) patient, and loss of follow-up in 1 (3.2%) patient. Paradoxical pyoderma gangrenosum was observed as an adverse effect in 1 patient that resolved after discontinuing SEC and starting infliximab. Conclusion: SEC appears to be an effective and safe treatment option for HS, especially when used in the early and mild stages of the disease and in biologic-naive patients.<\/jats:p>","DOI":"10.5826\/dpc.1501a4915","type":"journal-article","created":{"date-parts":[[2025,1,29]],"date-time":"2025-01-29T12:47:17Z","timestamp":1738154837000},"page":"4915","source":"Crossref","is-referenced-by-count":5,"title":["Secukinumab Treatment in Patients With Hidradenitis Suppurativa in Real-World Clinical Settings: A Multicenter Study"],"prefix":"10.5826","volume":"15","author":[{"given":"Ece","family":"Erba\u011fc\u0131","sequence":"first","affiliation":[{"name":"U\u015fak University Training and Research Hospital, Department of Dermatology and Venereology, U\u015fak"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zge Sevil","family":"Karstarl\u0131 Bakay","sequence":"first","affiliation":[{"name":"Pamukkale University Faculty of Medicine, Department of Dermatology and Venereology, Denizli"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatma Asl\u0131","family":"Hapa","sequence":"first","affiliation":[{"name":"Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital, Department of Dermatology and Venereology, Izmir"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"27750","published-online":{"date-parts":[[2025,1,29]]},"reference":[{"key":"10.5826\/dpc.1501a4915_ref1","doi-asserted-by":"crossref","unstructured":"Goldburg SR, Strober BE, Payette MJ. Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. May 2020;82(5):1045-1058. DOI:10.1016\/j.jaad.2019.08.090. PMID: 31604104.","DOI":"10.1016\/j.jaad.2019.08.090"},{"key":"10.5826\/dpc.1501a4915_ref2","doi-asserted-by":"crossref","unstructured":"Vossen A, van der Zee HH, Prens EP. Hidradenitis Suppurativa: A Systematic Review Integrating Inflammatory Pathways Into a Cohesive Pathogenic Model. Front Immunol. 2018;9:2965. DOI:10.3389\/fimmu.2018.02965. PMID: 30619323. PMCID: PMC6302105.","DOI":"10.3389\/fimmu.2018.02965"},{"key":"10.5826\/dpc.1501a4915_ref3","doi-asserted-by":"crossref","unstructured":"Melnik BC, John SM, Chen W, Plewig G. T helper 17 cell\/regulatory T\u2010cell imbalance in hidradenitis suppurativa\/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities. British Journal of Dermatology. 2018;179(2):260-272. DOI:10.1111\/bjd.16561","DOI":"10.1111\/bjd.16561"},{"key":"10.5826\/dpc.1501a4915_ref4","doi-asserted-by":"crossref","unstructured":"Matusiak \u0141, Szcz\u0119ch J, Bieniek A, Nowicka-Suszko D, Szepietowski JC. Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents. J Am Acad Dermatol. Apr 2017;76(4):670-675. DOI:10.1016\/j.jaad.2016.10.042","DOI":"10.1016\/j.jaad.2016.10.042"},{"key":"10.5826\/dpc.1501a4915_ref5","doi-asserted-by":"crossref","unstructured":"Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. Mar 4 2023;401(10378):747-761. DOI:10.1016\/s0140-6736(23)00022-3","DOI":"10.1016\/S0140-6736(23)00022-3"},{"key":"10.5826\/dpc.1501a4915_ref6","unstructured":"Novartis Europharm Limited. Cosentyx\u00ae (secukinumab): summary of product characteristics. Accessed 2.4.2024, https:\/\/www.ema.europa.eu\/en\/documents\/overview\/cosentyx-epar-medicine-overview_en.pdf"},{"key":"10.5826\/dpc.1501a4915_ref7","unstructured":"Novartis Europharm Limited. Cosentyx\u00ae (secukinumab) Biologic License Application (BLA): 761349. Accessed 2.4.2024, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/125504s066,761349s004lbl.pdf"},{"key":"10.5826\/dpc.1501a4915_ref8","doi-asserted-by":"crossref","unstructured":"Kimball AB, Jemec GB, Yang M, et al. Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment. Br J Dermatol. Dec 2014;171(6):1434-42. DOI:10.1111\/bjd.13270","DOI":"10.1111\/bjd.13270"},{"key":"10.5826\/dpc.1501a4915_ref9","doi-asserted-by":"crossref","unstructured":"Zouboulis CC, Passeron T, Pariser D, et al. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials. Br J Dermatol. May 17 2024;190(6):836-845. DOI:10.1093\/bjd\/ljae098","DOI":"10.1093\/bjd\/ljae098"},{"key":"10.5826\/dpc.1501a4915_ref10","doi-asserted-by":"crossref","unstructured":"Prussick L, Rothstein B, Joshipura D, et al. Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa. Br J Dermatol. Sep 2019;181(3):609-611. DOI:10.1111\/bjd.17822","DOI":"10.1111\/bjd.17822"},{"key":"10.5826\/dpc.1501a4915_ref11","doi-asserted-by":"crossref","unstructured":"Casseres RG, Prussick L, Zancanaro P, et al. Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial. J Am Acad Dermatol. Jun 2020;82(6):1524-1526. DOI:10.1016\/j.jaad.2020.02.005","DOI":"10.1016\/j.jaad.2020.02.005"},{"key":"10.5826\/dpc.1501a4915_ref12","doi-asserted-by":"crossref","unstructured":"Reguia\u00ef Z, Fougerousse AC, Maccari F, B\u00e9cherel PA. Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). J Eur Acad Dermatol Venereol. Nov 2020;34(11):e750-e751. DOI:10.1111\/jdv.16605","DOI":"10.1111\/jdv.16605"},{"key":"10.5826\/dpc.1501a4915_ref13","doi-asserted-by":"crossref","unstructured":"Melgosa Ramos FJ, Garc\u00eda Ruiz R, Est\u00e9banez Corrales A, Mateu Puchades A. Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: A retrospective single-centre case series (23 patients). J Eur Acad Dermatol Venereol. Apr 2023;37(4):e517-e519. DOI:10.1111\/jdv.18685","DOI":"10.1111\/jdv.18685"},{"key":"10.5826\/dpc.1501a4915_ref14","doi-asserted-by":"crossref","unstructured":"Martora F, Marasca C, Cacciapuoti S, et al. Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study. Clin Cosmet Investig Dermatol. 2024;17:159-166. DOI:10.2147\/ccid.S449367","DOI":"10.2147\/CCID.S449367"},{"key":"10.5826\/dpc.1501a4915_ref15","doi-asserted-by":"crossref","unstructured":"Ribero S, Ramondetta A, Fabbrocini G, et al. Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol. Jul 2021;35(7):e441-e442. DOI:10.1111\/jdv.17178","DOI":"10.1111\/jdv.17178"},{"key":"10.5826\/dpc.1501a4915_ref16","doi-asserted-by":"crossref","unstructured":"Roccuzzo G, Repetto F, Giordano S, et al. Anti-IL17 Secukinumab in hidradenitis suppurativa: A long-term drug survival analysis. Exp Dermatol. Jul 2024;33(7):e15140. DOI:10.1111\/exd.15140","DOI":"10.1111\/exd.15140"},{"key":"10.5826\/dpc.1501a4915_ref17","doi-asserted-by":"crossref","unstructured":"Haselgruber S, Fern\u00e1ndez-Crehuet-Serrano P, Fern\u00e1ndez-Ballesteros MD, et al. Insights into the Window of Opportunity and Outcome Measures in Patients with Moderate to Severe Hidradenitis Suppurativa Treated with Secukinumab: A Real-World Study. Dermatol Ther (Heidelb). Jun 19 2024. DOI:10.1007\/s13555-024-01209-w","DOI":"10.1007\/s13555-024-01209-w"},{"key":"10.5826\/dpc.1501a4915_ref18","doi-asserted-by":"crossref","unstructured":"Abu Rached N, Haven Y, Ocker L, Stockfleth E, Bechara FG. Real-world data about secukinumab in hidradenitis suppurativa: tobacco pack years an underestimated factor. Clin Exp Dermatol. Sep 21 2024. DOI:10.1093\/ced\/llae386","DOI":"10.1093\/ced\/llae386"},{"key":"10.5826\/dpc.1501a4915_ref19","doi-asserted-by":"crossref","unstructured":"Marasca C, Megna M, Balato A, Balato N, Napolitano M, Fabbrocini G. Secukinumab and hidradenitis suppurativa: Friends or foes? JAAD Case Rep. Feb 2019;5(2):184-187. DOI:10.1016\/j.jdcr.2018.12.002","DOI":"10.1016\/j.jdcr.2018.12.002"},{"key":"10.5826\/dpc.1501a4915_ref20","doi-asserted-by":"crossref","unstructured":"Thorlacius L, Theut Riis P, Jemec GBE. Severe hidradenitis suppurativa responding to treatment with secukinumab: a case report. Br J Dermatol. Jul 2018;179(1):182-185. DOI:10.1111\/bjd.15769","DOI":"10.1111\/bjd.15769"},{"key":"10.5826\/dpc.1501a4915_ref21","doi-asserted-by":"crossref","unstructured":"Schuch A, Fischer T, Boehner A, Biedermann T, Volz T. Successful Treatment of Severe Recalcitrant Hidradenitis Suppurativa with the Interleukin-17A Antibody Secukinumab. Acta Derm Venereol. Jan 12 2018;98(1):151-152. DOI:10.2340\/00015555-2794","DOI":"10.2340\/00015555-2794"},{"key":"10.5826\/dpc.1501a4915_ref22","doi-asserted-by":"crossref","unstructured":"J\u00f8rgensen AR, Yao Y, Thomsen SF. Therapeutic Response to Secukinumab in a 36-Year-Old Woman with Hidradenitis Suppurativa. Case Rep Dermatol Med. 2018;2018:8685136. DOI:10.1155\/2018\/8685136","DOI":"10.1155\/2018\/8685136"},{"key":"10.5826\/dpc.1501a4915_ref23","doi-asserted-by":"crossref","unstructured":"Villegas-Romero I, Collantes-Rodr\u00edguez C, Valenzuela-Ubi\u00f1a S, Jim\u00e9nez-Gallo D. Moderate to Severe Hidradenitis Suppurativa Successfully Treated With Secukinumab. Actas Dermosifiliogr (Engl Ed). Oct 2020;111(8):696-698. Hidradenitis supurativa moderada-grave tratada exitosamente con secukinumab. DOI:10.1016\/j.ad.2019.07.007","DOI":"10.1016\/j.ad.2019.07.007"},{"key":"10.5826\/dpc.1501a4915_ref24","doi-asserted-by":"crossref","unstructured":"Kridin K, Shani M, Schonmann Y, et al. Psoriasis and hidradenitis suppurativa: A large-scale population-based study. J Am Acad Dermatol. May 2023;88(5):e231-e236. DOI:10.1016\/j.jaad.2018.11.036","DOI":"10.1016\/j.jaad.2018.11.036"},{"key":"10.5826\/dpc.1501a4915_ref25","doi-asserted-by":"crossref","unstructured":"Nguyen TV, Damiani G, Orenstein LAV, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. Jan 2021;35(1):50-61. DOI:10.1111\/jdv.16677","DOI":"10.1111\/jdv.16677"},{"key":"10.5826\/dpc.1501a4915_ref26","doi-asserted-by":"crossref","unstructured":"Avc\u0131 C, Ak\u0131n G, Akarsu S, Lebe B. Pyoderma gangrenosum and Beh\u00e7et's-like disease induced by secukinumab: a paradoxical drug reaction. J Dermatolog Treat. Dec 2023;34(1):2235040. DOI:10.1080\/09546634.2023.2235040","DOI":"10.1080\/09546634.2023.2235040"},{"key":"10.5826\/dpc.1501a4915_ref27","doi-asserted-by":"crossref","unstructured":"Clemente-Hern\u00e1ndez B, \u00c1lvarez-Salafranca M, Muelas-Rives I, Ollero-Domenche L, Gracia-Caza\u00f1a T, Gilaberte Y. Multifocal pyoderma gangrenosum induced by secukinumab in a patient with hidradenitis suppurativa. Indian J Dermatol Venereol Leprol. Jul 25 2024:1-3. DOI:10.25259\/ijdvl_329_2024","DOI":"10.25259\/IJDVL_329_2024"},{"key":"10.5826\/dpc.1501a4915_ref28","doi-asserted-by":"crossref","unstructured":"Orita A, Hoshina D, Hirosaki K. Pyoderma gangrenosum caused by secukinumab successfully treated with risankizumab: a case report and literature review. Clin Exp Dermatol. Jul 2022;47(7):1372-1374. DOI:10.1111\/ced.15183","DOI":"10.1111\/ced.15183"},{"key":"10.5826\/dpc.1501a4915_ref29","doi-asserted-by":"crossref","unstructured":"Petty AJ, Whitley MJ, Balaban A, Ellington K, Marano AL. Pyoderma gangrenosum induced by secukinumab in a patient with psoriasis successfully treated with ustekinumab. JAAD Case Rep. Aug 2020;6(8):731-733. DOI:10.1016\/j.jdcr.2020.06.011","DOI":"10.1016\/j.jdcr.2020.06.011"},{"key":"10.5826\/dpc.1501a4915_ref30","doi-asserted-by":"crossref","unstructured":"Wollina U, Sch\u00f6nlebe J, F\u00fcrll C. Pyoderma gangrenosum induced by secukinumab-A late paradoxical drug reaction. Dermatol Ther. Jan 2020;33(1):e13161. DOI:10.1111\/dth.13161","DOI":"10.1111\/dth.13161"},{"key":"10.5826\/dpc.1501a4915_ref31","doi-asserted-by":"crossref","unstructured":"Jin K, Matsuzaki Y, Akasaka E, Nakano H, Sawamura D. Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. J Dermatol. Mar 2019;46(3):e108-e109. DOI:10.1111\/1346-8138.14611","DOI":"10.1111\/1346-8138.14611"},{"key":"10.5826\/dpc.1501a4915_ref32","doi-asserted-by":"crossref","unstructured":"Benzaquen M, Monnier J, Beaussault Y, Rouby F, Berbis P. Pyoderma gangrenosum arising during treatment of psoriasis with adalimumab: Effectiveness of ustekinumab. Australas J Dermatol. Nov 2017;58(4):e270-e271. DOI:10.1111\/ajd.12545","DOI":"10.1111\/ajd.12545"},{"key":"10.5826\/dpc.1501a4915_ref33","doi-asserted-by":"crossref","unstructured":"Guenova E, Teske A, Fehrenbacher B, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. Oct 2011;147(10):1203-5. DOI:10.1001\/archdermatol.2011.168","DOI":"10.1001\/archdermatol.2011.168"},{"key":"10.5826\/dpc.1501a4915_ref34","doi-asserted-by":"crossref","unstructured":"Alavi A, French LE, Davis MD, Brassard A, Kirsner RS. Pyoderma Gangrenosum: An Update on Pathophysiology, Diagnosis and Treatment. Am J Clin Dermatol. Jun 2017;18(3):355-372. DOI:10.1007\/s40257-017-0251-7","DOI":"10.1007\/s40257-017-0251-7"}],"container-title":["Dermatology Practical &amp; Conceptual"],"original-title":[],"link":[{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/4915\/3007","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/4915\/3471","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/download\/4915\/3007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T10:23:56Z","timestamp":1762511036000},"score":1,"resource":{"primary":{"URL":"https:\/\/dpcj.org\/index.php\/dpc\/article\/view\/4915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,29]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5826\/dpc.1501a4915","relation":{"has-manifestation":[{"id-type":"other","id":"1-78-4915-g3007","asserted-by":"subject"},{"id-type":"other","id":"1-78-4915-g3471","asserted-by":"subject"}],"is-part-of":[{"id-type":"doi","id":"10.5826\/dpc.v15i1","asserted-by":"subject"}]},"ISSN":["2160-9381"],"issn-type":[{"value":"2160-9381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,29]]},"article-number":"16"}}